Search result for 'taro pharmaceutical industries'

Sun Pharma arm, Taro, recalls over 17,000 units of antifungal shampoo in the US due to manufacturing issues. USFDA report details the recall.

Sun Pharma has completed the merger of Taro Pharmaceutical Industries, making Taro a wholly-owned subsidiary. The deal, valued at $347.73 million, brings together two pharmaceutical giants.

Sun Pharma to acquire remaining 21.52% stake in Taro Pharmaceutical Industries for Rs 2,891.76 crore, enabling the merger of the two entities.

Sun Pharma has revised its offer to acquire Taro Pharmaceutical Industries for USD 43 per share in cash, up from USD 38 per share. The deal is subject to shareholder approval.